Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Active Pass Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

A biotech start-up seeking to establish itself in the area of Alzheimer's disease (AD) faces the daunting task of competing in an arena already populated by a contingent of large drug companies that are expending considerable resources in the hopes of developing the sort of blockbuster product with which Big Pharma is so obsessed. But Peter Reiner, VMD, PhD, president and CEO of Active Pass Pharmaceuticals Inc., argues that his company can carve a niche for itself with a novel technology for treating AD that may also provide a platform for developing therapeutics in a number of other major disease areas.

You may also be interested in...



New Approaches for Neurodegenerative Disorders

Neurodegenerative disorders represent a tremendous unmet medical need. Millions of people are affected by such diseases as Alzheimer's, Huntington's Parkinson's, MS and ALS, not to mention those suffering the neurodegenerative effects of stroke and spinal cord injury. And because many of these diseases are age-related, the already staggering numbers of patients will increase during the next several years as increasing life expectancies and changing demographics increase the percentage of older Americans. The market for neuroscience therapies is currently the fastest growing segment in pharmaceuticals, and is projected to become the leading therapeutic area within five years. Small wonder that new companies are entering the fray, hoping to capture a share of this multi-billion dollar opportunity as well as to finally offer a cure to the victims of these diseases.

AureoGen Biosciences Inc.

Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.

Pain Therapeutics

Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090283

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel